EMEA-001222-PIP01-11-M01

Opinion/decision on a Paediatric investigation plan (PIP): Constella, linaclotide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0529/2022

Opinion/decision on a Paediatric investigation plan (PIP): Uplizna, Inebilizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0206/2024

EMEA-003196-PIP01-22-M01

Opinion/decision on a Paediatric investigation plan (PIP): Vanflyta, Quizartinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0203/2024

EMEA-003480-PIP01-23

EMEA-003586-PIP01-24

EMEA-003535-PIP02-24

EMEA-003408-PIP02-24

Opinion/decision on a Paediatric investigation plan (PIP): Ebglyss, Lebrikizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Respiratory, thoracic and mediastinal disorders, PIP number: P/0212/2024